Related Experiment Videos
Prognostic indicators in node-negative early stage breast cancer
W W Wong1, S Vijayakumar, R R Weichselbaum
1Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Illinois 60637.
The American Journal of Medicine
|May 1, 1992
Summary
Identifying prognostic factors in early-stage, node-negative breast cancer is crucial. This helps select patients who benefit from adjuvant therapy, avoiding unnecessary toxicity and cost for those with a low recurrence risk.
Area of Science:
- Oncology
- Medical Research
- Genetics
Background:
- Screening mammography increases early-stage, node-negative breast cancer diagnoses.
- While many are cured, approximately 30% experience distant recurrence.
- Adjuvant systemic therapy can reduce recurrence but requires careful patient selection.
Purpose of the Study:
- To review clinical and pathological prognostic factors for early-stage, node-negative breast cancer.
- To identify patient subsets with low recurrence risk who may not benefit from adjuvant therapy.
Main Methods:
- Review of clinical and pathological prognostic factors.
- Analysis of factors including tumor size, grades, receptor status, menopausal status, proliferative rate, HER-2/neu amplification, and cathepsin D levels.
Main Results:
- Favorable factors: tumor size ≤ 2 cm, low grades, low S-phase fraction, diploidy, low cathepsin D, positive estrogen/progesterone receptors.
- HER-2/neu overexpression role remains controversial and requires further investigation.
- These factors can identify low-risk patients.
Conclusions:
- Prognostic factors aid in selecting node-negative breast cancer patients for adjuvant therapy.
- Identification of low-risk patients can prevent unnecessary treatment, toxicity, and cost.
- Further research is needed for definitive role of HER-2/neu in prognosis.